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250Comparison of Latanoprostene Bunod 0.024%
and Timolol Maleate 0.5% in Open-Angle
Glaucoma or Ocular Hypertension: The LUNAR
StudyFELIPE A. MEDEIROS, KEITH R. MARTIN, JAMES PEACE, BALDO SCASSELLATI SFORZOLINI,
JASON L. VITTITOW, AND ROBERT N. WEINREB PURPOSE: To compare the intraocular pressure (IOP)-
lowering effect of latanoprostene bunod (LBN) 0.024%
with timolol maleate 0.5% in subjects with open-angle
glaucoma (OAG) or ocular hypertension (OHT).
 DESIGN: Prospective, randomized, double-masked,
parallel-group, noninferiority clinical trial.
 METHODS: Adults with OAG or OHT from 46 clinical
sites (United States and European Union) were random-
ized 2:1 to LBN instilled once daily (QD) in the evening
and vehicle in the morning or timolol instilled twice a day
(BID) for 3 months. IOP was measured at week 2, week
6, and month 3 (8 AM, 12 PM, and 4 PM each visit).
 RESULTS: A total of 387 subjects (LBN, n [ 259;
timolol, n [ 128) completed the study. Analysis of
covariance showed that mean IOP reduction with LBN
was not only noninferior to timolol but significantly
greater (P £ .025) than timolol at all but the first time
point in this study (week 2, 8 AM). Of LBN- and
timolol-treated subjects, respectively, 31.0% and 18.5%
(P[ .007) had their IOP reduced ‡25% from baseline,
and 17.7% and 11.1% (P[ .084) had their IOP reduced
to £18 mm Hg over all time points/visits in this study.
Ocular treatment-emergent adverse events, while uncom-
mon, appeared more frequently in the LBN group (all
mild-moderate except 1 case of severe hyperemia).
 CONCLUSIONS: LBN 0.024% QD in the evening was
noninferior to timolol 0.5% BID over 3 months of
treatment, with significantly greater IOP lowering in
subjects with OAG or OHT at all but the earliest
time point evaluated, and demonstrated a goodupplemental Material available at AJO.com.
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ATANOPROSTENE BUNOD (LBN; BOL-303259-X;
Bausch þ Lomb) is a novel nitric oxide–donating
prostaglandin F2a analogue. The compound is
rapidly metabolized into latanoprost acid, a prostaglandin
analogue, and butanediol mononitrate, a nitric oxide
(NO)-donating moiety, following exposure to esterases in
the ocular environment.1 Prostaglandin analogues and
NO donors have both demonstrated intraocular pressure
(IOP)-lowering effects in animals and humans.2–13
Latanoprost (Xalatan; Pfizer Inc, New York, New York,
USA), which is hydrolyzed in the cornea to latanoprost
acid, is indicated for the reduction of elevated IOP in
patients with open-angle glaucoma (OAG) and ocular hy-
pertension (OHT).14 Data indicate that the effects of LBN
on IOP are mediated via actions on both nonconventional
and conventional aqueous outflow pathways.Whereas lata-
noprost reduces IOP by increasing the outflow of aqueous
fluid primarily through the uveoscleral pathway (noncon-
ventional route),15–22 NO donors are reported to induce
relaxation of the trabecular meshwork and the Schlemm’s
canal, which increases aqueous humor outflow through
the conventional pathway.2,4,5,12,13,23–28
In 3 preclinical models of ocular hypertension (laser-
induced ocular hypertensive nonhuman primate, glaucom-
atous dog, and transiently ocular hypertensive rabbit),
topical administration of LBN rapidly lowered IOP.1 The
rabbit model was insensitive to equimolar latanoprost,
suggesting that the effects of LBN in this model were solely
mediated by NO. Further, the IOP-lowering effects of LBN
were greater than those of equimolar doses of latanoprost in
both glaucomatous dogs and ocular hypertensive primates,
presumably owing to the action of NO. In a randomized,
investigator-masked, parallel-group, dose-ranging, phase 2
clinical study in 413 patients with OAG or OHT, LBN
ophthalmic solution 0.024% reduced mean diurnal IOP
to a significantly greater extent than latanoprost 0.005%
(Xalatan) over 28 days of treatment.29 This improvement0002-9394
http://dx.doi.org/10.1016/j.ajo.2016.05.012
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in IOP reduction with LBN 0.024% relative to latanoprost
0.005% in human subjects with OAG or OHT confirmed
preclinical findings, providing additional support for a
pharmacologic effect of NO released from the NO-
donating portion of the LBN molecule.
The objective of this phase 3 study was to compare the
IOP-lowering effect of LBN 0.024% instilled once daily
(QD) in the evening with timolol maleate 0.5% (hereafter
referred to as timolol 0.5%) instilled twice daily (BID) in
subjects with OAG or OHT. Another recent phase 3 trial
with a similar design (the APOLLO study)30 found that
LBNQD in the eveningwas significantly better than timolol
0.5% BID with regard to IOP lowering throughout the day.METHODS
 STUDY DESIGN: The LUNAR study (Clinicaltrials.gov
identifier: NCT01749930) was a randomized, multicenter,
double-masked, parallel-group, clinical study conducted at
46 investigational sites in the United States (40), the
United Kingdom (3), Germany (2), and Italy (1) between
January 28, 2013 and November 26, 2014. The study was
conducted in accordance with Good Clinical Practices
(as described in the International Conference onHarmoni-
zation guidelines), the ethical principles of the Declaration
of Helsinki, the Code of Federal Regulations, and appli-
cable local regulations. Institutional Review Board/Ethics
Committee approval was obtained at each participating
site, and all study subjects provided written informed con-
sent prior to participation. The primary objective of the
study was to evaluate the noninferiority of the mean
IOP-lowering effect of LBN 0.024% over 3 months of treat-
ment to that of timolol 0.5%. If noninferiority of LBN
0.024% was achieved, the secondary objective was to eval-
uate the statistical superiority of LBN 0.024% to timolol
0.5%. The study was composed of 2 phases: a 3-month
active controlled efficacy phase followed by a 3-month
open-label safety extension phase, the results of which
will be published separately.
 SUBJECTS: The study enrolled male and female subjects
>_18 years of age with a diagnosis of OAG (including
pigmentary or pseudoexfoliative) or OHT in 1 or both
eyes. Intraocular pressure was assessed once at visit 1
(Screening) and at 8 AM, 12 PM, and 4 PM during visit
3 (Eligibility, Day 0) to establish baseline and eligibility
values. Subjects who were already receiving treatment
with an IOP-lowering medication were required to un-
dergo a washout period prior to visit 3, the duration of
which varied depending on the type of IOP-lowering medi-
cation used (maximum washout period, 28 þ 5 days). At
visit 3, and following washout, if required, study partici-
pants were required to have an IOP >_26 mm Hg at a min-
imum of 1 of 3 time points (8 AM, 12 PM, and 4 PM),VOL. 168 LATANOPROSTENE BUNOD FOR LOWE>_24 mm Hg at a minimum of 1 time point, and >_22 mm
Hg at 1 time point, all in the same eye, and IOP
<_36 mm Hg at all 3 measurement time points in both
eyes. Potential subjects undergoing washout were excluded
from participation in the study if IOP exceeded 36 mm Hg
in either eye at any point during the washout period.
Eligible subjects also had a best-corrected visual acuity
(BCVA) of þ 0.7 logarithm of the minimal angle of reso-
lution (logMAR) units (Snellen equivalent of approxi-
mately 20/100) or better in either eye.
Subjects were ineligible for study participation if they
were involved in another clinical trial during this study,
or were involved in another clinical trial within 30 days
prior to visit 1 (Screening), for subjects requiring a washout
period, or 30 days prior to visit 3 (Eligibility, Day 0) for sub-
jects not requiring a washout period. Subjects were also
excluded if they had known hypersensitivity or contraindi-
cation to the active or inactive ingredients of the study
treatments; were unable to discontinue contact lens use
or other eye drop medications (eg, artificial tears) during
and for 15 minutes after instillation of study drug and dur-
ing study visits; had a central corneal thickness >600 mm
in either eye; had any condition that prevented reliable
applanation tonometry (eg, significant corneal surface ab-
normalities) in either eye; or had advanced glaucoma
(cup-to-disc ratio>0.8 or split fixation) or other significant
ophthalmic disease. The study also excluded subjects who
required treatment with ocular or systemic corticosteroids,
subjects in need of or expected to require additional topical
or systemic treatment for OAG or OHT, and subjects with
an anticipated need to initiate or modify medication
known to affect IOP (eg, b-adrenergic antagonists,
a-adrenergic agonists, calcium channel blockers,
angiotensin-converting enzyme A inhibitors and angio-
tensin II receptor blockers) during the study.
 STUDY TREATMENTS AND ASSESSMENTS: The investi-
gational product LBN 0.024%, its vehicle, and the compar-
ator timolol 0.5% were manufactured by Bausch & Lomb
Inc (Tampa, Florida, USA). Baseline demographic and
clinical data (ie, relevant medical and ocular history,
concomitant medications, ocular assessments) were
recorded at visit 1 (Screening). The study eye was defined
as the eye that qualified per inclusion criteria at visit 3
(Eligibility, Day 0). If both eyes qualified, the study eye
was the eye with the higher mean diurnal IOP value
(defined as average of IOPs recorded at 8 AM, 12 PM,
and 4 PM) at visit 3, or the right eye if both eyes had the
same mean diurnal IOP value. If both eyes of a subject
had a diagnosis of OAG or OHT, then both eyes were
treated for the duration of the study, even if only 1 eye
met study inclusion criteria at visit 3.
Eligible subjects were randomized at visit 3 in a 2:1 ratio to
receive 3 months of treatment with LBN 0.024%QD in the
evening (approximately 8 PM) and vehicle QD in the
morning (approximately 8 AM) or timolol 0.5% BID.251RING OF INTRAOCULAR PRESSURE
Each subject received study kits containing 4 eye drop bot-
tles with computer-generated investigational labels (ie,
void of commercial labeling) and was instructed to instill 1
drop of study drug from the ‘‘Night’’ dosing bottle into the
affected eye(s) at approximately 8 PM each evening and 1
drop from the ‘‘Day’’ dosing bottle at approximately 8 AM
each morning. A randomization schedule was created prior
to any study enrollment by a statistician not otherwise
involved in the study using SAS(SAS Institute,Cary,North
Carolina, USA; Version 9.2). Allocation of study drug was
completed through the use of IRT (Interactive Response
Technology), which determined which kit to assign to
each subject. Subjects and study site personnel were fully
masked to treatment assignments. Compliance was deter-
mined as actual number of instillations, as recorded on a pa-
tient diary, divided by number of expected instillations.
Subjects completed 3 study visits (visit 4 [week 26 2days];
visit 5 [week 6 6 3 days]; visit 6 [month 3 6 10 days])
following randomization. Intraocular pressure was assessed
at each visit in both eyes at 8 AM, 12 PM, and 4 PM using
a Goldman applanation tonometer. On these days, the AM
dose of study drug was instilled after the first IOP assessment
of the day. Intraocular pressure was measured twice consecu-
tively and the mean IOP was recorded for consecutive mea-
surements within 2 mm Hg. In cases of consecutive
measurements differing by>2 mmHg, a third measurement
was taken and the median IOP was recorded. Whenever
possible, IOP was measured by the same operator using the
same tonometer at each visit for a given subject.
Safety assessments recorded at each visit included ocular
and systemic treatment-emergent adverse events (TEAEs),
vital sign measurements, BCVA (measured using the
ETDRS standard protocol), and slit-lamp examination; in
addition, ophthalmoscopy and specular microscopy were
performed at day 0 and month 3. Conjunctival hyperemia
was graded by the investigator on a 1-4 photographic refer-
ence (none, mild, moderate, severe) scale prior to IOP
assessment at each time point/study visit.
 ENDPOINTS: The primary efficacy endpoint was the IOP
in the study eye measured at the specified time points
of 8 AM, 12 PM, and 4 PM at each postrandomization visit
(week 2, week 6, and month 3). Secondary efficacy end-
points included the proportion of eyes with IOP <_18 mm
Hg; the proportion with IOP reduction >_25% from baseline
consistently across all 9 postrandomization assessments;
change from baseline in IOP at 8 AM, 12 PM, and 4 PM;
and the change from baseline in diurnal IOP at week 2,
week 6, and month 3. Safety endpoints included the inci-
dence of ocular and systemic adverse events (AEs), vital
signs, BCVA, and conjunctival hyperemia assessments.
 STATISTICALANALYSIS: A sample size of 300 subjects in
the per-protocol (PP) population was calculated as
providing adequate power (90%) to detect an IOP differ-
ence (noninferiority margin) of 1.5 mm Hg, assuming a252 AMERICAN JOURNAL OFstandard deviation (SD) of 3.75 mm Hg and a 2-sided
a ¼ 0.05. The SD was obtained by pooling the SD from
an LBN 0.024% phase 2b study29 and the timolol arm of
a phase 3 study.31 A total of 393 subjects were to be ran-
domized in a 2:1 ratio to the LBN 0.024% and timolol
0.5% treatment groups, respectively, to account for poten-
tial protocol violations and dropouts.
The primary efficacy analyses were performed using anal-
ysis of covariance (ANCOVA) in the intent-to-treat
(ITT) population (ie, all randomized subjects who instilled
at least 1 dose of study drug and had a baseline and at least 1
postrandomization IOP), with randomized treatment group
as a classification variable and time-matched mean IOP as a
covariate. Missing data were imputed using the last-
observation-carried-forward (LOCF) method for the IOP
in the study eye measured at 8 AM, 12 PM, and 4 PM at
each postrandomization visit. The 2 treatments, LBN
0.024% and timolol 0.5%, were compared for each time
point at each visit by determining the least squares (LS)
mean of each treatment group, the difference in the LS
mean (LBN 0.024% – timolol 0.5%), and the 2-sided
95% confidence interval (CI) for the difference. Noninfer-
iority was to be established if the upper limit of the CIs for
the difference did not exceed 1.5 mmHg at all 9 IOP assess-
ments and did not exceed 1.0 mm Hg for at least 5 out of
the 9 time points. If noninferiority was determined, superi-
ority was concluded if the upper limit of the 95%CI did not
exceed 0 mm Hg at any of the 9 IOP measurement time
points. These analyses were repeated in the PP population
in order to supplement the primary analyses.
Analyses of the secondary endpoints were performed
following demonstration of noninferiority of LBN
0.024% to timolol 0.5%. The proportion of subjects with
IOP <_18 mm Hg at all 9 postrandomization IOP measure-
ment time points and the proportion with IOP reduction
>_25% at all 9 time points were summarized categorically.
The percentage reduction from baseline in IOP was calcu-
lated as 100 3 (baseline mean IOP  postbaseline mean
IOP)/baseline mean IOP. For each secondary endpoint,
the 2-sided 95% CI around the difference in proportions
(LBN 0.024%  timolol 0.5%) and the P value from the
Pearson x2 test were presented. An ANCOVA of change
from baseline in IOP was performed with fixed-effect terms
for treatment and baseline for the 3 postrandomization
time points (8 AM, 12 PM, and 4 PM) at visit 4/week 2,
visit 5/week 6, and visit 6/month 3. An ANCOVA of
change from baseline in mean diurnal IOP was also
performed with fixed-effect terms for treatment and diurnal
baseline IOP at each postrandomization visit.
Safety analyses were performed on the safety population,
which included all randomized subjects who instilled at
least 1 dose of study drug. All AEs were coded using Med-
ical Dictionary for Regulatory Activities dictionary version
13.0. Ocular TEAEs were summarized for study eyes and
treated fellow eyes separately by treatment group. Nonocu-
lar TEAEs were summarized for each treatment group usingAUGUST 2016OPHTHALMOLOGY
FIGURE 1. Disposition of patients with open-angle glaucoma or ocular hypertension receiving latanoprostene bunod 0.024% or
timolol 0.5%. aIn 2 latanoprostene bunod (LBN) subjects, including the subject excluded from the intent-to-treat (ITT) population,
the study eye could not be derived according to the protocol definition. Thus, the number of evaluable study eyes was n[ 277 for both
the safety and ITT populations. bIn 1 timolol subject, the study eye could not be derived according to the protocol definition. Thus, the
number of evaluable study eyes was n[ 135 for both the safety and ITT populations.discrete summaries at the subject and event level by system
organ class and preferred term. Ocular and nonocular
TEAEs were summarized by relationship to study drug
and severity. Data on BCVA, conjunctival hyperemia,
slit-lamp biomicroscopy, and ophthalmoscopy were
presented separately for study eyes and treated fellow eyes
and summarized using descriptive statistics (BCVA) or
categorically (conjunctival hyperemia, slit-lamp bio-
microscopy, and ophthalmoscopy). Conjunctival hyper-
emia was classified as none, mild, moderate, or severe
through the use of photographic standards.
All CIs, statistical tests, and resulting P values were re-
ported as 2-sided and were evaluated at the 5% significance
level. Continuous data were summarized with descriptive
statistics (number, mean, SD, median, minimum, and
maximum). Statistical analyses were conducted using
SAS software (SAS Institute, Cary, North Carolina,
USA) version 9.2 or higher.RESULTS
 SUBJECTS: Of 756 subjects screened, 420 were enrolled
and randomized to LBN 0.024% (n ¼ 283) or timololVOL. 168 LATANOPROSTENE BUNOD FOR LOWE0.5% (n¼ 137), and 387 (92.1%) completed the 3 months
of study treatment (Figure 1). Overall, 415 subjects
received at least 1 instillation of study drug and comprised
the safety population. The ITT population included 414
subjects (LBN 0.024%, n ¼ 278; timolol 0.5%, n ¼ 136).
The proportion of subjects in the ITT population who
completed the study was similar in the LBN 0.024%
(259/278; 93.2%) and timolol 0.5% (128/136; 94.1%)
groups.
In the ITT population, subjects were on average 64.7
years of age (range, 23–88 years) and were predominantly
female (58.2%), white (70.8%), and non-Hispanic/non-
Latino (86.7%; Table 1). Black/African-American
subjects comprised 27.8% of the overall population. De-
mographic and baseline eye characteristics (mean
corneal thickness, refraction sphere, and refraction cylin-
der) were comparable between treatment groups. The
majority of subjects (72%) had been treated with
IOP-lowering medications within 30 days prior to enroll-
ment. Nonocular medical history was similar between
the treatment groups. Baseline mean (SD) diurnal IOP
(average of IOP at 8 AM, 12 PM, and 4 PM) was 26.6
(2.4) mm Hg for subjects randomized to LBN 0.024%
and 26.4 (2.3) mm Hg for subjects randomized to
timolol 0.5%.253RING OF INTRAOCULAR PRESSURE
TABLE 1. Demographics and Baseline Ocular Characteristics of Subjects Randomized to Latanoprostene Bunod 0.024%, Timolol
0.5% and Overall (Intent-to-Treat Population)
Latanoprostene Bunod 0.024% (n ¼ 278) Timolol 0.5% (n ¼ 136) Total (N ¼ 414)
Demographics
Age, y
Mean (SD) 65.0 (9.77) 64.1 (9.71) 64.7 (9.75)
Median (range) 66.0 (23–87) 65.0 (37–88) 65.0 (23–88)
Age group, n (%)
<65 years 127 (45.7) 64 (47.1) 191 (46.1)
>_65 years 151 (54.3) 72 (52.9) 223 (53.9)
Sex, n (%)
Male 116 (41.7) 57 (41.9) 173 (41.8)
Female 162 (58.3) 79 (58.1) 241 (58.2)
Race, n (%)
White 204 (73.4) 89 (65.4) 293 (70.8)
Black or African-American 69 (24.8) 46 (33.8) 115 (27.8)
Asian 4 (1.4) 1 (0.7) 5 (1.2)
Other 1 (0.4) 0 1 (0.2)
Ethnicity, n (%)
Hispanic or Latino 36 (12.9) 19 (14.0) 55 (13.3)
Non-Hispanic and non-Latino 242 (87.1) 117 (86.0) 359 (86.7)
On IOP-lowering medication at
enrollment, n (%)a
Yes 196 (70.5) 102 (75.0) 298 (72.0)
No 82 (29.5) 34 (25.0) 116 (28.0)
Baseline Ocular Characteristicsb
Mean corneal thickness, mm
Mean (SD) 550.17 (31.11) 551.18 (32.67) 550.50 (31.59)
Median 551.33 556.33 553.66
Min, max 470, 598.66 436, 598.66 436, 589.66
Diurnal intraocular pressure, mm Hg,
mean (SD) 26.6 (2.39) 26.4 (2.30) 26.5 (2.36)
IOP ¼ intraocular pressure; SD ¼ standard deviation.
aPrevious IOP-lowering medication categories: prostaglandin analogues (80.9%), b-blockers/combination drugs with a b-blocker (24.2%),
sympathomimetics (7.4%), and miotics or carbonic anhydrase inhibitors (14.1%).
bStudy eye could not be derived for 2 subjects; latanoprostene bunod n ¼ 277; timolol n ¼ 135 for baseline ocular characteristics. EFFICACY: Primary endpoint. The mean IOP in the
study eye was significantly lower in the LBN 0.024%
group than in the timolol 0.5% group at the majority of
time points measured (12 PM, 4 PM at week 2, 8 AM,
12 PM, 4 PM at week 6 and month 3) (Figure 2 and
Table 2). Noninferiority of LBN 0.024% to timolol
0.5% was demonstrated based on ANCOVA results
(upper limit of the 95% CIs did not exceed 1.0 mm Hg
at any of the 9 time points) (Table 2). LBN 0.024%
also met the criteria for statistical superiority over
timolol 0.5% at all time points except the 8 AM time
point at week 2 (upper limit of the 95% CI exceeded
0 mm Hg at this single assessment point) (Table 2).
Results in the PP population were consistent with these
findings (data not shown). Further exploratory analysis
indicated that the primary endpoint results did not254 AMERICAN JOURNAL OFdiffer based on prior IOP-lowering medication treatment
status at enrollment or whether or not subjects on
concurrent systemic b-blockers (15.1% of LBN and
13.2% of timolol subjects) were included in the analysis
(data not shown).
Secondary endpoints. The percentage of subjects with an
IOP reduction >_25% consistently at all 9 time points was
significantly higher in the LBN group (31.0%) compared
with the timolol group (18.5%; difference of proportions
12.5%; 95% CI of the difference: 4.0%, 21.1%; P ¼ .007)
(Figure 3). The percentage of subjects with mean IOP
<_18 mm Hg consistently at all 9 time points did not
differ in the LBN group compared with the timolol group
(17.7% vs 11.1%, respectively; difference of proportions,
6.6%; 95% CI: 0.4%, 13.5%; P ¼ .084) (Figure 3).AUGUST 2016OPHTHALMOLOGY
FIGURE 2. Least squares (LS) mean of mean intraocular pressure (IOP) (mm Hg) and standard error in the study eye by visit, time
point, and treatment group among subjects treated with latanoprostene bunod 0.024% (LBN) once daily (n[ 278) or timolol maleate
0.5% twice daily (n[ 136). Data represent intent-to-treat population with last observation carried forward. *P £ .025, analysis of
covariance of treatment difference.Further, ANCOVA showed that the treatment differ-
ence for the change from baseline in IOP was significantly
greater in the LBN 0.024% group than in the timolol
0.05% group at all time points (IOP range 7.5
to 8.8 mm Hg for LBN 0.024%; 6.6 to 7.9 mm Hg
for timolol 0.5%; P <_ .025) except for the 8 AM measure-
ment at week 2 (8.3 mm Hg for LBN 0.024%
vs7.9 mmHg for timolol 0.5%; P¼ .216). These changes
corresponded to a reduction from baseline ranging from
29.1% to 32.1% in the LBN 0.024% group and ranging
from 25.2% to 28.7% in the timolol treatment group
(Supplemental Table; Supplemental Material available at
AJO.com).
Mean diurnal IOP was significantly lower in the LBN
0.024% group compared with the timolol 0.5% group at
each visit (18.6 mm Hg vs 19.2 mm Hg at week 2,
18.2 mm Hg vs 19.1 mm Hg at week 6, and 18.1 mm Hg
vs 19.3 mm Hg at month 3; P <_ .034 for all). Similar to
the change from baseline at individual time points, the
mean change from baseline in mean diurnal IOP was signif-
icantly greater in the LBN 0.024% group than in the
timolol 0.5% group at each postrandomization study visit
(week 2, difference, 0.6 mm Hg; P ¼ .034; week 6,
difference, 0.9 mm Hg; P ¼ .002; month 3,
difference, 1.2 mm Hg; P < .001).
 SAFETY: In the safety population, the mean (SD) days of
exposure to the study drug was 88.8 (17.6) days in the LBN
0.024% group and 91.4 (14.9) days in the timolol 0.5%
group.VOL. 168 LATANOPROSTENE BUNOD FOR LOWEThe percentage of subjects experiencing at least 1 ocular
TEAE in the study eye appeared greater in the LBN 0.024%
group than in the timolol 0.5% group (Table 3). The most
frequently reported ocular TEAEs in LBN-treated study
eyes were conjunctival hyperemia, eye irritation, and eye
pain. Only 2 subjects in the LBN 0.024% group experi-
enced ocular TEAEs in the study eye that were considered
unrelated to the study drug; all other TEAEs were consid-
ered treatment-related. With the exception of 1 incident
of severe conjunctival hyperemia in the LBN 0.024% group
that was considered possibly related to the study drug,
all ocular TEAEs in the study eye were mild or moderate
in severity.
At least 1 ocular TEAE in the treated fellow eye was
experienced by 24.8% of subjects in the LBN 0.024% group
and 13.4% of those in the timolol 0.5% group. As with the
study eye, the most commonly reported ocular TEAEs in
the treated fellow eye were conjunctival hyperemia
(9.3% LBN 0.024%, 0.7% timolol 0.5%), eye irritation
(7.0% LBN 0.024%, 4.5% timolol 0.5%), and eye pain
(6.7% LBN 0.024%, 3.0% timolol 0.5%). The percentage
of subjects experiencing at least 1 treatment-related ocular
TEAE in the treated fellow eye appeared greater in the
LBN 0.024% group (23.3%) than in the timolol 0.5%
group (12.7%). One subject in the LBN 0.024% group
experienced severe conjunctival hyperemia that was
possibly related to the study drug; all other ocular TEAEs
in the treated fellow eye were mild or moderate in severity.
Nonocular TEAEs were reported for 36 of 278 (12.9%)
LBN subjects and 18 of 136 (13.2%) timolol 0.5% subjects,255RING OF INTRAOCULAR PRESSURE
TABLE 2. Analysis of Covariance Results for Comparison of Mean Intraocular Pressure in the Study Eye by Visit and Time Point
(Intent-to-Treat Population With Last Observation Carried Forward)
Least Squares Mean of the Mean IOP, mm Hg
Treatment Difference (95% Confidence Interval) P ValueLatanoprostene Bunod 0.024% Timolol 0.5%
Week 2
8 AM 19.2 19.6 0.4 (1.1, 0.3) .216
12 PM 18.5 19.2 0.8 (1.4, 0.1) .022
4 PM 18.1 18.8 0.7 (1.3, 0.1) .025
Week 6
8 AM 18.7 19.6 0.9 (1.6, 0.3) .005
12 PM 18.0 18.9 0.8 (1.5, 0.2) .007
4 PM 17.9 18.9 1.0 (1.6, 0.4) .003
Month 3
8 AM 18.7 19.6 0.9 (1.5, 0.3) .006
12 PM 17.9 19.2 1.3 (1.9, 0.7) <.001
4 PM 17.7 19.1 1.3 (2.0, 0.7) <.001
ANCOVA ¼ analysis of covariance; IOP ¼ intraocular pressure.
Least squaresmean of themean IOP, 95%confidence intervals, and P values were from an ANCOVAmodel with treatment as a classification
variable and time-matched baseline mean IOP as a covariate.
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FIGURE3. Percentage of subjects achieving a mean intraocular
pressure (IOP) £18 mm Hg and percentage of subjects with a
change from baseline (CFB) in IOP ‡25% at all 9 assessment
time points in 387 subjects with open-angle glaucoma or ocular
hypertension treated with latanoprostene bunod 0.024% once
daily (n [ 278) or timolol maleate 0.5% twice daily (n [
136). Data represent intent-to-treat population with last obser-
vation carried forward. *P[ .007.none of which were considered related to study treatment
except for 6 events in 5 of 278 (1.8%) LBN subjects (mada-
rosis, chest discomfort, dysgeusia, headache, insomnia, and
dyspnea) and 4 events in 2 of 136 (1.5%) timolol subjects
(headache [2 events], dizziness, somnolence). In the LBN
group, 15 severe nonocular TEAEs were reported (coronary
artery disease, cholelithiasis, fall in 2 subjects, head injury,256 AMERICAN JOURNAL OFjoint dislocation in 2 subjects, scapular fracture, skin lacer-
ation, subdural hemorrhage, ulna fracture, arthralgia,
convulsion, subarachnoid hemorrhage, and pulmonary em-
bolism) and were considered unrelated or unlikely related
to the study drug. One severe nonocular TEAE (headache)
occurred in the timolol 0.5% group and was considered
possibly related to the study drug. All other nonocular
TEAEs were mild or moderate in severity.
Overall, 4 serious TEAEs were reported by 4 subjects
(left shoulder subluxation/scapular fracture/fall, coronary
artery disease, hepatobiliary disorders, and head injury in
the LBN 0.024% group); none were considered related to
the study drug. No deaths occurred during the 3-month ef-
ficacy phase.
There were 4 study discontinuations secondary to AEs in
the LBN 0.024% group; 1 was deemed definitely related to
the study drug (ocular hyperemia), while 3 were deemed
probably related to the study drug (increased insomnia/res-
piratory disorder, blurred vision/instillation site pain,
periocular rash). There was 1 AE-associated study discon-
tinuation in the timolol 0.5% group (dizziness/headache),
which was deemed possibly related to the study drug.
Vital sign measurements were similar between treatment
groups with no treatment-related trends observed.
LogMAR BCVA did not vary during the study. Study eye
mean (SD) logMAR BCVA in LBN and timolol treatment
groups was 0.09 (0.14) and 0.07 (0.12) at baseline and 0.08
(0.12) and 0.07 (0.13) at 3 months, respectively.
At baseline, 36.8% of subjects in the LBN group and
40.7% of subjects in the timolol group were found to
have hyperemia in the study eye, mostly mild, as evaluated
by the investigator. At each posttreatment visit, the per-
centage of subjects with investigator-assessed conjunctivalAUGUST 2016OPHTHALMOLOGY
TABLE 3.Ocular Treatment-Emergent Adverse Events (TEAEs) Occurring in the Study Eye of >_1%of Subjects in any Treatment Group
(Safety Population)
Latanoprostene Bunod 0.024%, n ¼ 277a n (%) Timolol Maleate 0.5%, n ¼ 135a n (%)
>_1 ocular TEAE 66 (23.8) 18 (13.3)
>_1 treatment-related ocular TEAE 64 (23.1) 18 (13.3)
Eye disorders
Conjunctival hyperemia 25 (9.0) 1 (0.7)
Eye irritation 20 (7.2) 6 (4.4)
Eye pain 16 (5.8) 5 (3.7)
Ocular hyperemia 7 (2.5) 1 (0.7)
Vision blurred 5 (1.8) 3 (2.2)
Eye pruritis 4 (1.4) 1 (0.7)
Asthenopia 0 2 (1.5)
Dry eye 3 (1.1) 1 (0.7)
Punctate keratitis 3 (1.1) 0
Foreign body sensation in eyes 3 (1.1) 0
Administration site conditions
Instillation site pain 4 (1.4) 0
Investigations
Corneal staining 3 (1.1) 0
aThe study eye could not be derived for 3 subjects (2 in the latanoprostene bunod group, 1 in the timolol group) in the Safety population; there
were no TEAEs reported for these subjects during the study.hyperemia was slightly higher in the LBN treatment group
compared with the timolol treatment group (week 2, 47.8%
vs 36.6%; week 6, 47.8% vs 34.1%; month 3, 48.3% vs
31.5%), as was the percentage of subjects with conjunctival
hyperemia considered moderate or severe (week 2, 6.2% vs
0.7%; week 6, 7.5% vs 3.0%; month 3, 6.5% vs 3.1%).
Similar results were found for the treated fellow eye (data
not shown).DISCUSSION
THE FINDINGS FROM THIS RANDOMIZED, MULTICENTER,
double-masked, parallel-group, clinical study demonstrate
that LBN ophthalmic solution 0.024% QD in the evening
effectively lowered IOP over 3 months of treatment in sub-
jects with OAG or OHT. Noninferiority to timolol 0.5%
BID was established by ANCOVA for the comparison of
mean IOP. Treatment with LBN also resulted in signifi-
cantly greater IOP lowering compared with timolol at all
assessed time points except for the first postbaseline assess-
ment at 8 AM/week 2 of treatment. As another measure of
efficacy, IOP reduction responses were evaluated by the
number of eyes demonstrating an IOP reduction that was
>_25% lower than the baseline value, and nearly twice as
many subjects achieved this level of reduction across all 9
time points in the LBN group compared with the timolol
group. Likewise, the percentage of subjects in whom IOPVOL. 168 LATANOPROSTENE BUNOD FOR LOWEdecreased to <_18 mm Hg across all 9 time points was
numerically higher in the LBN group compared with the
timolol group, although the difference was not statistically
significant.
Both LBN and timolol were well tolerated during the
3-month efficacy phase of this study. Although low overall,
ocular AEs appeared more frequently in the LBN group and
were mainly attributable to reports of conjunctival hyper-
emia and ocular irritation. Conjunctival hyperemia and
ocular irritation were also the most commonly noted AEs
reported with LBN use in another similarly designed
3-month, phase 3 comparison of LBN and timolol in 387
subjects with OAG or OHT.30 Rates of hyperemia reported
as an adverse event with LBN in the latter study30 (2.8%–
3.6%) were generally similar to those observed with timolol
(1.5%–2.2%) and were lower than reported in the current
study. According to investigator assessments, conjunctival
hyperemia was present at baseline in about 40% of subjects
in both the current and prior study30 and showed slight var-
iations in prevalence over 3 months of treatment, with
LBN use associated with slightly higher rates compared
with timolol. Conjunctival hyperemia is commonly
encountered with the use of ocular antihypertensive ther-
apy32 including latanoprost,33,34 and was therefore not
unexpected whether reported as an AE or through
prospective investigator evaluation. Other ocular AEs
were infrequent and observed among similar proportions
of patients in both study groups. Other safety outcomes
were unremarkable.257RING OF INTRAOCULAR PRESSURE
Landmark studies such as the Ocular Hypertension Treat-
ment Study (OHTS),35 the Early Manifest Glaucoma Trial
(EMGT),36,37 the Canadian Glaucoma Study,38 and the
United Kingdom Glaucoma Treatment Study (UKGTS)11
have demonstrated that in glaucoma suspects or patients
with manifest glaucoma, the onset and/or progression of vi-
sual field loss and optic disc deterioration can be delayed by
lowering IOP. Further, estimates based on some of these
studies suggest that each 1 mm Hg reduction in IOP is asso-
ciated with an approximate 10%–19% reduction in the risk
for glaucoma progression.37–39 In both the current study
and the previously reported phase 3 trial with similar
design,30 there was an additional 1.2 mm Hg reduction in
diurnal IOPwith LBNas comparedwith timolol at 3months.
Further, IOP lowering observed with LBN 0.024% in these
phase 3 studies30 ranged from 7.5 to 9.1 mm Hg reductions
from baseline over 3 months of treatment. The IOP reduc-
tions in the current study corresponded to percent decreases
from baseline for LBN 0.024% ranging from 29% to 32%.
While phase 3 studies did not evaluate IOP lowering of
LBN against the most commonly used glaucoma medica-
tion, latanoprost, a mixed treatment comparison258 AMERICAN JOURNAL OFmeta-analysis of randomized controlled trials evaluating
the IOP-lowering efficacy of prostaglandin analogues found
an additional mean IOP lowering of 1.0 mm Hg for latano-
prost over timolol after 3 months of treatment.40 However,
the ability to compare the current data with this meta-
analysis is limited by multiple factors, including differences
in baseline IOP and study design. Of note, a recent head-to-
head phase 2 clinical trial compared the IOP-lowering
efficacy of LBN to latanoprost in patients with primary
open-angle glaucoma and OAG. A statistically significant
additional IOP lowering of 1.2 mm Hg was observed for
LBN over latanoprost at 28 days.29
In conclusion, the findings of this study demonstrate that
LBN 0.024% once daily in the evening is noninferior to
timolol 0.5% administered twice daily and results in signif-
icantly greater IOP lowering over 3 months of treatment in
subjects with OAG or OHT. In addition, LBN 0.024%
treatment resulted in a significantly greater reduction in
mean diurnal IOP than timolol 0.5% over the course of
the study. LBN was well tolerated overall and exhibited a
safety profile typical of topical prostaglandin analogue
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